Literature DB >> 25986471

Interpretation of the Expected Value of Perfect Information and Research Recommendations: A Systematic Review and Empirical Investigation.

Joanna Thorn1, Joanna Coast2, Lazaros Andronis2.   

Abstract

BACKGROUND: Expected value of perfect information (EVPI) calculations are increasingly performed to guide and underpin research recommendations. An EVPI value that exceeds the estimated cost of research forms a necessary (although not sufficient) condition for further research to be considered worthwhile. However, it is unclear what factors affect researchers' recommendations and whether there is a notional threshold of positive returns below which research is not recommended. The objectives of this study were to explore whether EVPI and other factors have a bearing on research recommendations and to assess whether there exists a threshold EVPI below which research is typically not recommended.
METHODS: A systematic literature review was undertaken to identify applied EVPI calculations in the health care field. Study characteristics were extracted, including funder, location, disease group, publication year, primary language, and outcome measure. Population EVPI values and willingness-to-pay thresholds were also extracted alongside verbatim text excerpts describing the authors' research recommendations. Recommendations were classified according to whether further research was recommended (a positive recommendation) or not (negative). Factors affecting the likelihood of a positive recommendation were examined statistically using logistic regression and visually by plotting the results in graphs. RESULTS AND
CONCLUSIONS: Eighty-six articles were included, of which 13 suggested no further research, 66 recommended further research, and 7 gave no recommendation. EVPI appears to be a key driver of researchers' recommendations for further research. Disease area, funder, study location, publication year, and outcome may have a bearing on recommendations, although none of these factors reached statistical significance. A threshold EVPI value below which research is typically not recommended was found at around £ 1.48 million.
© The Author(s) 2015.

Entities:  

Keywords:  decision rules; research recommendations; value of information

Mesh:

Year:  2015        PMID: 25986471     DOI: 10.1177/0272989X15586552

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  9 in total

1.  Cost-Effectiveness of Treatments for the Management of Bone Metastases: A Systematic Literature Review.

Authors:  Lazaros Andronis; Ilias Goranitis; Sue Bayliss; Rui Duarte
Journal:  Pharmacoeconomics       Date:  2018-03       Impact factor: 4.981

2.  Cost-effectiveness of direct surgery versus preoperative octreotide therapy for growth-hormone secreting pituitary adenomas.

Authors:  Shaun J Kilty; Myriam G M Hunink; Lisa Caulley; Eline Krijkamp; Mary-Anne Doyle; Kednapa Thavorn; Fahad Alkherayf; Nick Sahlollbey; Selina X Dong; Jason Quinn; Stephanie Johnson-Obaseki; David Schramm
Journal:  Pituitary       Date:  2022-08-27       Impact factor: 3.599

3.  How can clinical researchers quantify the value of their proposed comparative research?

Authors:  Anirban Basu; David L Veenstra; Josh J Carlson; Wei-Jhih Wang; Kelley Branch; Jeffrey Probstfield
Journal:  Am Heart J       Date:  2018-12-08       Impact factor: 4.749

4.  Cost-Utility Analysis of Prophylactic Dextrose Gel vs Standard Care for Neonatal Hypoglycemia in At-Risk Infants.

Authors:  Matthew J Glasgow; Richard Edlin; Jane E Harding
Journal:  J Pediatr       Date:  2020-07-04       Impact factor: 4.406

5.  Cost-effectiveness of cognitive-behavioural therapy for sleep disorder added to usual care in patients with schizophrenia: the BEST study.

Authors:  Apostolos Tsiachristas; Felicity Waite; Daniel Freeman; Ramon Luengo-Fernandez
Journal:  BJPsych Open       Date:  2018-04-19

6.  Cost-effectiveness of integrated disease management for high risk, exacerbation prone, patients with chronic obstructive pulmonary disease in a primary care setting.

Authors:  Andrew D Scarffe; Christopher J Licskai; Madonna Ferrone; Kevin Brand; Kednapa Thavorn; Doug Coyle
Journal:  Cost Eff Resour Alloc       Date:  2022-08-12

7.  Adjuvant Statin Therapy for Esophageal Adenocarcinoma: A Cost-Utility Analysis.

Authors:  Rebekah Fong Soe Khioe; Chris Skedgel; Andrew Hart; Michael Philip Nelson Lewis; Leo Alexandre
Journal:  Pharmacoeconomics       Date:  2018-03       Impact factor: 4.981

8.  Testing strategies for Lynch syndrome in people with endometrial cancer: systematic reviews and economic evaluation.

Authors:  Chris Stinton; Mary Jordan; Hannah Fraser; Peter Auguste; Rachel Court; Lena Al-Khudairy; Jason Madan; Dimitris Grammatopoulos; Sian Taylor-Phillips
Journal:  Health Technol Assess       Date:  2021-06       Impact factor: 4.014

9.  Cost-effectiveness analysis of oral nutritional supplements with nutritional counselling in head and neck cancer patients undergoing radiotherapy.

Authors:  Beatrice Martin; Emanuele Cereda; Riccardo Caccialanza; Paolo Pedrazzoli; Rosanna Tarricone; Oriana Ciani
Journal:  Cost Eff Resour Alloc       Date:  2021-06-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.